BMYBristol-Myers SquibbRunning, no new patients
A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)
Myelofibrosis
3Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2.6
2 insiders sold shares within a month
Since Sep 9, 2026 · was worth 5, fading over time
Worry score3
Score over time
- Stage
- Phase 1/2
- Patients
- 216 (planned)
- Started
- Mar 22, 2021
- Main results expected
- Aug 31, 2028
- Fully finished
- Aug 31, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Incidence of adverse events (AEs)
Measured over: Up to 52 months
Incidence of serious adverse events (SAEs)
Measured over: Up to 52 months
Incidence of AEs meeting protocol-defined dose-limiting toxicity (DLT) criteria
Measured over: Up to 26 months
Incidence of AEs leading to discontinuation
Measured over: Up to 52 months
Incidence of death
Measured over: Up to 52 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2.6, since 2026-09-09, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04817007 · record last updated 2026-05-08 · checked 2026-11-09 15:47 UTC